Why the study?
Does ajmaline challenge unmask the Brugada phenotype in patients with LQT3 caused by the SCN5A-E1784K mutation?
Population
23 subjects from 4 unrelated families with a family history of sudden cardiac death and familial diagnosis…
Comparison
Ajmaline challenge vs Non-carriers of the SCN5A-E1784K mutation
Design
Cohort
Authors
Loading...
Ajmaline challenge may identify Brugada overlap before Class I drugs in LQT3-E1784K; leaves open standardized screening protocols.
Does ajmaline challenge unmask the Brugada phenotype in patients with LQT3 caused by the SCN5A-E1784K mutation?
Ajmaline challenge unmasks a high rate of Brugada syndrome overlap in patients with LQT3 caused by the SCN5A-E1784K mutation, highlighting the importance of this test before initiating sodium channel blockers.
Hohmann et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: